Gapping up
In reaction to earnings/guidance:
- CECE +12%, MTSI +11.1%, OUT +10%, AVLR +8.7%, EVRI +8.6%, DIOD +8%, MTCH +7.3%, EA +6.8%, EVH +6.6%, ANDX +6.6%, ATRO +6.3%, SGMS +6%, CBRE +5.7%, ODP +5.4%, QRVO +5.2%, PAGP +5.1%, CTRE +3.7%, UFCS +3.5%, MCK +3.4%, BTG +3.3%, FUN +3.3%, NCR +3%, JAZZ +2.9%, KGC +2.9%, PZZA +2.8%, PEN +2.6%, PAA +2.3%, EDIT +2.3%, FANG +2.2%, BG +2%, BCOR +1.7%, BECN +1.6%, CRZO +1.5%, PUMP +1.5%, TWO +1.4%, GOLD +1.4%, ESPR +1.3%, RCKT +1.3%, JCOM +1.1%
Other news:
- AKCA +6.8% (Akcea Therapeutics and Ionis Pharma (IONS) announce OLE data from the NEURO-TTR study of TEGSEDI in patients with hereditary ATTR amyloidosis (hATTR) with polyneuropathy)
- ANDX +6.6% (to be acquired by MPLX (MPLX) in a unit-for-unit transaction representing an equity value of approximately $9 bln)
- CYH +4.8% (Chairman/CEO disclosed the purchase of nearly 1 mln shares worth more than $3 mln)
- TXMD +4.7% (after closing more than 16% lower on the day)
- BYND +3.2% (continued momentum)
- ZM +2.2% (authorization under the US Federal Risk and Authorization Management Program has been approved, with the sponsorship of the US Department of Homeland Security)
- TTWO +1.1% (EA sympathy)
Analyst comments:
- MOS +2.6% (upgraded to Overweight from Neutral at JP Morgan)